Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease

This article was originally published in Scrip

Executive Summary

Gilead Sciences Inc. knows a thing or two about developing successful liver disease therapies, since it owns the world's top two hepatitis C drugs in terms of sales, and now the company is attempting to dominate another liver disease with the purchase of Nimbus Apollo Inc. for up to $1.2bn.


Related Content

Gilead May Have Better Takeover Targets Than Tesaro
Gilead Data Suggest Role For ACC Inhibition In NASH
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Deal Watch: Takeda Continues Transaction Spree With Four More Deals
Intercept Increases Chance Of Success In NASH Without Significant Delay
Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses
Top M&A Of 2016: Cast Your Vote!
Priority Review Vouchers Appear To Be Dropping In Price





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts